RIGL · Rigel Pharmaceuticals Inc
$47.15
+0.18 (+0.38%)
At close · Oct 2
Return incl. dividend (before tax)
Market Cap
$900.00M
Shares
18.68M
Volume · Oct 2
185.67K
Avg daily vol (3M)
301.34K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$47.15
Open$47.66
Day$46.45–48.00
52W close$25.44–50.96
Avg vol 30d249K
Short int3.2M · 17.1% float · 15.8d
Short vol76%
Last earningsAug 4, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 4
Up next
Next earnings call
Nov 3, 2026
Est · unconfirmed
· in 4 wks
filed Aug 4, 2026
call held Aug 4, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$276.79M
Trailing 12 months
Net income (TTM)
$321.91M
Trailing 12 months
Revenue growth YoY
-22.6%
Year over year
Operating margin
31.5%
Trailing 12 months
P / E (TTM)
2.8
Trailing earnings · reciprocal yield 35.8%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+7.8%
Year over year · more shares
Price change (1Y)
+67.7%
Trailing year
Short interest
17.1%
Latest settlement · 15.8 days to cover
AI Brief
Q2 FY26 earnings call · Aug 4, 2026
Q2 FY26
TL;DR. Rigel reported Q2 net product sales of $67.0 million (+14% YoY) and net income of $17.3 million, in-licensed and is preparing the mid-August U.S. launch of VEPPANU, and raised its 2026 total revenue guidance to $285–$295 million while reiterating an expected full-year profit.
Bullish
- + Net product sales rose 14% YoY to $67.0 million in Q2 2026.
- + TAVALISSE net product sales grew 18% YoY to $47.4 million.
- + REZLIDHIA net product sales grew 27% YoY to $8.9 million.
- + Rigel raised 2026 total revenue guidance to approximately $285–$295 million from the prior $275–$290 million range.
- + VEPPANU in-license expands commercial portfolio, with U.S. commercial availability expected in mid-August.
- + Company continues to anticipate positive full-year 2026 net income while funding new and existing programs.
Bearish
- − Q2 net income fell to $17.3 million from $59.6 million a year ago, due largely to a prior-year $40.0M Lilly collaboration release.
- − GAVRETO net product sales declined 10% YoY to $10.7 million.
- − Total costs and expenses rose 36% YoY to $55.1 million, driven by higher personnel, R&D, and Arvinas/Pfizer-license costs.
- − Cash, cash equivalents and short-term investments fell to $95.3 million at June 30, 2026 from $155.0 million at December 31, 2025, partly reflecting a $70.0 million upfront payment to Arvinas and Pfizer.
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Strong
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+29%
above
Price vs 50-day avg
+6%
above
RSI (14)
52
neutral
MACD trend
Negative
52-week position
85%
near high
Momentum
relative strength
1-month return
−3%
trailing
6-month return
+57%
trailing
YTD return
+10%
this year
Relative strength
+45%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $44 › 200d $37 — 50d above 200d
Institutional flow
Flat
1 of 157 funds reported for Sep 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
17.09% of float · ▲ +0.3% MoM · 15.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
157 holders — mid 3-yr range
Squeeze score
77
high risk · 0–100
Fundamentals
Revenue growth
+64%
Y/Y
EPS growth
+1868%
Y/Y
Free cash flow
$75.2M
Valuation
P/E 2.9
below peers
Balance sheet
$11.9M
net debt
Quant / Vol
risk profile
Volatility
63%
annualized · 1-yr
Max drawdown
−50%
past year
ATR
3.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 4, 2026
Total revenues
· 2026
$285M – $295M
prior FY $294.28M
midpoint −1.5% Y/Y
Net product sales
· 2026
$255M – $265M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+29%
Bullish
Price vs 50-day avg
+6%
Bullish
RSI (14)
52
Neutral
MACD trend
Negative
Bearish
52-week position
85%
Bullish
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross)
No cross
50d $44 › 200d $37 — 50d above 200d
Institutional flow
Flat
1 of 157 funds reported for Sep 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
17.09% of float · ▲ +0.3% MoM · 15.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
157 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $25
Now $47 · 85%
Range high $51
vs 200-day avg +29%
vs 50-day avg +6%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RIGL
this stock
Rigel Pharmaceuticals Inc
|
$900.00M | +10.1% | +64.1% | 2.9 | 17.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RIGL | -2.1% | -2.8% | +57.3% | -2.1% | +10.1% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -1.9% | -2.3% | +45.1% | -3.0% | -2.8% |